[
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Announces Libre Technology Reduces Heart Hospitalization Risk for Diabetics",
    "summary": "Abbott Laboratories (NYSE:ABT) has recently announced compelling study findings about its FreeStyle Libre® technology, which show a decrease in hospitalization risks for diabetes patients, potentially reducing healthcare costs. This news underscores the positive advancements in the company’s product line. Meanwhile, recent earnings with a reported increase in both sales and net income, alongside reaffirmed growth guidance, reflect a strong financial position. In the broader market, index...",
    "url": "https://finnhub.io/api/news?id=0814bd205539e85d5c26d5b0e268f831b2fbc3ba4bad74aa15b6a6cedc0b2f27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747330757,
      "headline": "Abbott Laboratories (NYSE:ABT) Announces Libre Technology Reduces Heart Hospitalization Risk for Diabetics",
      "id": 134483647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) has recently announced compelling study findings about its FreeStyle Libre® technology, which show a decrease in hospitalization risks for diabetes patients, potentially reducing healthcare costs. This news underscores the positive advancements in the company’s product line. Meanwhile, recent earnings with a reported increase in both sales and net income, alongside reaffirmed growth guidance, reflect a strong financial position. In the broader market, index...",
      "url": "https://finnhub.io/api/news?id=0814bd205539e85d5c26d5b0e268f831b2fbc3ba4bad74aa15b6a6cedc0b2f27"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=acc56b4fa06878ae15df4c48f9b10617b7eab2cccf69231cd6882813975132e8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747326600,
      "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "id": 134488260,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=acc56b4fa06878ae15df4c48f9b10617b7eab2cccf69231cd6882813975132e8"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes",
    "summary": "Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. For the first time, data show that CGM technology can help lessen the severity of cardiovascular complications – regardless of a prior history of low blood sugar events or heart disease-related hospitalizations –",
    "url": "https://finnhub.io/api/news?id=65aef4a72a6a22a98ea3e100db590b50ece8df6e24eb13140dcec4689e6d90a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747314300,
      "headline": "Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes",
      "id": 134483648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. For the first time, data show that CGM technology can help lessen the severity of cardiovascular complications – regardless of a prior history of low blood sugar events or heart disease-related hospitalizations –",
      "url": "https://finnhub.io/api/news?id=65aef4a72a6a22a98ea3e100db590b50ece8df6e24eb13140dcec4689e6d90a8"
    }
  },
  {
    "ts": null,
    "headline": "MotoAmerica is Changing Concussion Safety",
    "summary": "The world's fastest sport is making a major shift into safety. MotoAmerica is the first sports organization to use Abbott's rapid blood test for concussion evaluation. It will be on site for all...",
    "url": "https://finnhub.io/api/news?id=46d951e69e719d9e5a7cb1494c6723a5bb9c981f0064f3d3a7bbad70e3f42c72",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747311488,
      "headline": "MotoAmerica is Changing Concussion Safety",
      "id": 134474540,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "The world's fastest sport is making a major shift into safety. MotoAmerica is the first sports organization to use Abbott's rapid blood test for concussion evaluation. It will be on site for all...",
      "url": "https://finnhub.io/api/news?id=46d951e69e719d9e5a7cb1494c6723a5bb9c981f0064f3d3a7bbad70e3f42c72"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories' (NYSE:ABT) institutional investors lost 4.0% last week but have benefitted from longer-term gains",
    "summary": "Key Insights Given the large stake in the stock by institutions, Abbott Laboratories' stock price might be vulnerable...",
    "url": "https://finnhub.io/api/news?id=ad4293d8c8f4738aab3b133e215227ebdd36393a4ec94ed77b1f5b77ee0224ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747306816,
      "headline": "Abbott Laboratories' (NYSE:ABT) institutional investors lost 4.0% last week but have benefitted from longer-term gains",
      "id": 134465703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Abbott Laboratories' stock price might be vulnerable...",
      "url": "https://finnhub.io/api/news?id=ad4293d8c8f4738aab3b133e215227ebdd36393a4ec94ed77b1f5b77ee0224ad"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Announces Results from Its Reflect Real-World Studies That Show the Use of Freestyle Libre®? Continuous Glucose Monitoring Technology",
    "summary": "Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre®? continuous glucose monitoring technology is associated with a significant reduction in the risk of...",
    "url": "https://finnhub.io/api/news?id=18809035f38a5b57378604165edd4be998bf891cccd9e056b6b4b7492d6d9ce1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747304429,
      "headline": "Abbott Announces Results from Its Reflect Real-World Studies That Show the Use of Freestyle Libre®? Continuous Glucose Monitoring Technology",
      "id": 134467892,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre®? continuous glucose monitoring technology is associated with a significant reduction in the risk of...",
      "url": "https://finnhub.io/api/news?id=18809035f38a5b57378604165edd4be998bf891cccd9e056b6b4b7492d6d9ce1"
    }
  }
]